



Curriculum Vitae

Personal information **Victoria Cerrada**

Work experience

- June 2025-Present: **Quality assessor**. Biological products, advanced therapies and biotechnology division. Medicines for Human Use Department at AEMPS (National agency of medicines of Spain).
- December 2024-June 2025: **Quality analyst** in the bioassay and microbiology team at Moderna Biotech (Spain). Mainly responsible for performing potency tests (ELISA) on commercialized mRNA products and release tests for stability studies. Additionally, responsible for writing validation and method transfer reports.
- August 2023- February 2024: **Analyst** at the microbiology department at **Defence Toxicology Institute** (Spain). Implementation of a novel technology for the early detection of biological risks such as Legionella and Vibrio Cholerae in drinking water for the Spanish army on missions using molecular biology technique (automatized DNA extraction and qPCR analysis).
- October 2017-January 2023: **Predoctoral researcher** in the Translational Research with iPSCs group at **Hospital 12 de Octubre** (Spain). Generation of a human skeletal muscle model of McArdle disease based on iPSC technology and its isogenic control generated with CRISPR-Cas9 techniques.

Education and training

- 2017-2023: **PhD** with Cum Laude in Biochemistry, Molecular Biology and Biotechnology. Complutense University of Madrid (Spain)
- 2014-2015: **Master's Degree** in Biochemistry, Molecular Biology, and Biotechnology. Complutense University of Madrid (Spain)
- 2008-2014: **Bachelor's Degree** in Biology. Complutense University of Madrid (Spain)
- 2007-2009: **Higher Technician** in Clinical Diagnostic Laboratory. Instituto Moratalaz (Spain)

Additional information

Publications

- **Cerrada V**, García-Consuegra I, Arenas J, Gallardo ME. **Creation of an iPSC-Based Skeletal Muscle Model of McArdle Disease Harboring the Mutation c.2392T>C (p.Trp798Arg) in the PYGM Gene**. Biomedicines. 2023 Aug 31;11(9):2434. doi: 10.3390/biomedicines11092434. PMID: 37760875; PMCID: PMC10525199.
- Ortuño-Costela MDC, **Cerrada V**, Moreno-Izquierdo A, García-Consuegra I, Laberthonnière C, Delourme M, Garesse R, Arenas J, Fuster García C, García García G, Millán JM, Magdinier F, Gallardo ME. **Generation of the First Human In Vitro Model for McArdle Disease Based on iPSC Technology**. Int J Mol Sci. 2022 Nov 12;23(22):13964. doi: 10.3390/ijms232213964. PMID: 36430443; PMCID: PMC9692531.
- **Cerrada V**, García-López M, Alvarez-Galeano S, Moreno-Izquierdo A, Lucia A, Rabasa Pérez M, Arenas J, Gallardo ME. **Generation of the iPSC line IISHDOI007-A from peripheral blood mononuclear cells from a patient with McArdle disease harbouring the mutation c.2392 T > C; p.Trp798Arg**. Stem Cell Res. 2020 Dec;49:102108. doi: 10.1016/j.scr.2020.102108. Epub 2020 Dec 3. PMID: 33370875.
- Ortuño-Costela MDC, **Cerrada V**, García-López M, Gallardo ME. **The Challenge of Bringing iPSCs to the Patient**. Int J Mol Sci. 2019 Dec 13;20(24):6305. doi: 10.3390/ijms20246305. PMID: 31847153; PMCID: PMC6940848.
- **Cerrada V**, García-López M, Moreno-Izquierdo A, Villaverde C, Zurita O, Martin-Merida MI, Arenas J, Ayuso C, Gallardo ME. **Derivation of a human DOA iPSC line, IISHDOI006-A, with a mutation in the ACO2 gene: c.1999G>A; p.Glu667Lys**. Stem Cell Res. 2019 Oct;40:101566. doi: 10.1016/j.scr.2019.101566. Epub 2019 Aug 29. PMID: 31509793.
- Del Carmen Ortuño-Costela M, García-López M, **Cerrada V**, Gallardo ME. **iPSCs: A powerful tool for skeletal muscle tissue engineering**. J Cell Mol Med. 2019 Jun;23(6):3784-3794. doi: 10.1111/jcmm.14292. Epub 2019 Apr 1. PMID: 30933431; PMCID: PMC6533516.
- Ortuño-Costela MDC, **Cerrada V**, García-López M, Arenas J, Martínez J, Lucia A, Garesse R, Gallardo ME. **Derivation of an aged mouse induced pluripotent stem cell line, IISHDOI005-A**. Stem Cell Res. 2019 Apr;36:101418. doi: 10.1016/j.scr.2019.101418. Epub 2019 Mar 12. PMID: 30897488.

Projects

Memberships

Other Relevant Information